-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$20.0031.32% Upside
Recent Analyst Forecasts and Stock Ratings
Travere Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Travere Therapeutics, Inc.?
Travere Therapeutics, Inc. has been rated by research analysts at Barclays, Guggenheim, H.C. Wainwright, Bank of America Securities, Canaccord Genuity, Piper Sandler in the past 90 days.